Virax Biolabs Targets 180-Day ViraxImmune™ Data Readout in $25B PAIS Market
Virax Biolabs is pursuing US market entry for its ViraxImmune™ PAIS diagnostic via an LDT pathway in a $25B PAIS market and targeting an assay readout within 180 days. The debt-free company holds $6.4M cash against a $2.6M market cap despite ISO certifications and FDA Q-Sub feedback.
1. Focused Strategy on ViraxImmune™ Development
Virax Biolabs is concentrating on advancing ViraxImmune™, its proprietary assay for diagnosing immune dysfunction in post-acute infection syndromes such as Long COVID and ME/CFS. Management has prioritized a US market-entry via a Laboratory Developed Test pathway, with broader IVD development planned after initial validation.
2. Clinical and Regulatory Milestones
Key operational milestones include fully recruited UK PAIS studies, completion of the FDA pre-submission Q-Sub meeting with constructive feedback, and ongoing clinical validation planning with Emory University. The company also achieved ISO 13485 and ISO 9001 certifications to support quality infrastructure.
3. Financial Position and Valuation
On March 31, 2026, Virax held approximately $6.4M in cash and remains debt-free, while its market capitalization stands around $2.6M. Management believes the current valuation fails to reflect progress toward the next key data readout and commercial milestones in a $25B diagnostic market.